Monocytes and macrophages: emerging mechanisms and novel therapeutic targets in pulmonary fibrosis

• Published in: American Journal of Physiology: Cell Physiology Vol. 325; no. 4; p. C1046
• Main Authors: Perrot, Carole Y, Karampitsakos, Theodoros, Herazo-Maya, Jose D
• Format: Journal Article
• Language: English
• Published: United States 01-10-2023
• Subjects: Cell Differentiation; Extracellular Matrix - pathology; Humans; Idiopathic Pulmonary Fibrosis - drug therapy; Idiopathic Pulmonary Fibrosis - genetics; Lung - pathology; Macrophages - pathology; Monocytes - pathology; monocytes; pathogenesis; macrophages; immunity; pulmonary fibrosis
• ISSN: 1522-1563
• DOI: 10.1152/ajpcell.00302.2023

Pulmonary fibrosis results from a plethora of abnormal pathogenetic events. In idiopathic pulmonary fibrosis (IPF), inhalational, environmental, or occupational exposures in genetically and epigenetically predisposed individuals trigger recurrent cycles of alveolar epithelial cell injury, activation of coagulation pathways, chemoattraction, and differentiation of monocytes into monocyte-derived alveolar macrophages (Mo-AMs). When these events happen intermittently and repeatedly throughout the individual's life cycle, the wound repair process becomes aberrant leading to bronchiolization of distal air spaces, fibroblast accumulation, extracellular matrix deposition, and loss of the alveolar-capillary architecture. The role of immune dysregulation in IPF pathogenesis and progression has been underscored in the past mainly after the disappointing results of immunosuppressant use in IPF patients; however, recent reports highlighting the prognostic and mechanistic roles of monocytes and Mo-AMs revived the interest in immune dysregulation in IPF. In this review, we will discuss the role of these cells in the onset and progression of IPF, as well as potential targeted therapies.